[{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Zevorcabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Loyal Valley Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Series C Financing","leadProduct":"Zevorcabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"CARsgen Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Loyal Valley Capital","highestDevelopmentStatusID":"15","companyTruncated":"CARsgen Therapeutics \/ Loyal Valley Capital"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Zevorcabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Collaboration","leadProduct":"Zevorcabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"CARsgen Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"CARsgen Therapeutics \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Zevorcabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Zevorcabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Zevorcabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Zevorcabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Car-Bcma T Cell","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ CARsgen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Car-Bcma T Cell","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Undisclosed","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ CARsgen Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"CARsgen Therapeutics \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Beijing Chao Yang Hospital | The First Affiliated Hospital of Soochow University | Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Tianjin Medical University General Hospital | First Affiliated Hospital of Zhejiang University | Beijing ","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Car-Bcma T Cell","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Beijing Chao Yang Hospital | The First Affiliated Hospital of Soochow University | Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Tianjin Medical University General Hospital | First Affiliated Hospital of Zhejiang University | Beijing ","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Beijing Chao Yang Hospital | The First Affiliated Hospital of Soochow University | Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Tianjin Medical University General Hospital | First Affiliated Hospital of Zhejiang University | Beijing "},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CAR-BCMA T Cell","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Zevor-Cel","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"CAR-CD19 T Cell","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ CARsgen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"First Affiliated Hospital of Zhejiang University | RenJi Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"CAR-CD19 T Cell","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARsgen Therapeutics \/ First Affiliated Hospital of Zhejiang University | RenJi Hospital","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ First Affiliated Hospital of Zhejiang University | RenJi Hospital"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"CAR-CD19 T Cell","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Undisclosed","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARsgen Therapeutics \/ CARsgen Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"CARsgen Therapeutics \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"KJ-C2219","moa":"CD19\/CD20","graph1":"Immunology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"KJ-C2219","moa":"CD19\/CD20","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ CARsgen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ CARsgen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ CARsgen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ CARsgen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Immunology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ CARsgen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CAR-T Cell Therapy","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARsgen Therapeutics \/ CARsgen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CAR-T Cell Therapy","moa":"Chimeric antigen receptor","graph1":"Immunology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARsgen Therapeutics \/ CARsgen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CAR-T Cell Therapy","moa":"Chimeric antigen receptor","graph1":"Immunology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARsgen Therapeutics \/ CARsgen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"CAR-CLD18 T Cell","moa":"Claudin-18 (CLDN18)","graph1":"Oncology","graph2":"Undisclosed","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CARsgen Therapeutics \/ CARsgen Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"CARsgen Therapeutics \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AB011","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"AB011","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Shanghai East Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AB011","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CARsgen Therapeutics \/ Shanghai East Hospital","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Shanghai East Hospital"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AB011","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"CAR-CLDN18.2 T Cell","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARsgen Therapeutics \/ CARsgen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CT041","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Collaboration","leadProduct":"Claudin18.2 mRNA Vaccine","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Preclinical","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Moderna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"CARsgen Therapeutics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"CAR-GPC3 T Cell","moa":"Glypican-3 (GPC3)","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ CARsgen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"CAR-GPC3 T Cell","moa":"Glypican-3 (GPC3)","graph1":"Oncology","graph2":"Undisclosed","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CARsgen Therapeutics \/ CARsgen Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"CARsgen Therapeutics \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"CAR-GPC3 T Cell","moa":"Glypican-3 (GPC3)","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Nanjing PLA 81 Hospital | First Affiliated Hospital of Zhejiang University | RenJi Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"CAR-GPC3 T Cell","moa":"Glypican-3 (GPC3)","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CARsgen Therapeutics \/ Nanjing PLA 81 Hospital | First Affiliated Hospital of Zhejiang University | RenJi Hospital","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Nanjing PLA 81 Hospital | First Affiliated Hospital of Zhejiang University | RenJi Hospital"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Shanghai Zhongshan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CAR-GPC3 T Cell","moa":"Glypican-3 (GPC3)","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CARsgen Therapeutics \/ Shanghai Zhongshan Hospital","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Shanghai Zhongshan Hospital"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Peking University Cancer Hospital & Institute | Fudan University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CARsgen Therapeutics \/ Peking University Cancer Hospital & Institute | Fudan University","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Peking University Cancer Hospital & Institute | Fudan University"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Fudan University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Autologous CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CARsgen Therapeutics \/ Fudan University","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Fudan University"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CT011","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CT0180","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARsgen Therapeutics \/ CARsgen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CT0181","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARsgen Therapeutics \/ CARsgen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CT048","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CARsgen Therapeutics \/ CARsgen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CT0590","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARsgen Therapeutics \/ CARsgen Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"CARsgen Therapeutics \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CT0594CP","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CARsgen Therapeutics \/ CARsgen Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"CARsgen Therapeutics \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CT0596","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CT071","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CT071","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by CARsgen Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
